Image For Activity Cover
SSO Webinar: The Role of the Surgical Oncologist in Locally Advanced and Metastatic Melanoma: Management of In-transit Disease and Current Status of Infusion/Perfusion in the Era of Immunotherapy (2020)
Activity Description/ Purpose

As there have been significant improvements in systemic therapy for advanced melanoma, the role of the surgical oncologist in multidisciplinary management is evolving. Topics to be addressed in this activity include the following: 1) Management of In-transit Disease and 2) Current Status of Limb Infusion/Perfusion in the Era of Immunotherapy.


The faculty for this activity are listed below:

Giorgos Karakousis, MD (Planner, Moderator)

Abramson Cancer Center/University of Pennsylvania


Christina Angeles, MD (Planner, Moderator)

University of Michigan


David Ollila, MD (Planner, Presenter)

The University of North Carolina


Jonathan Zager, MD (Planner, Presenter)

Moffitt Cancer Center

Target Audience

This activity is intended for all surgeons and other health care professionals who are involved in the treatment of patients with melanoma.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Summarize the current management recommendations for in-transit melanoma.
  • Discuss the role of infusion and perfusion in the management of recurrent and metastatic melanoma.

The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The Society of Surgical Oncology designates this internet enduring material for a maximum of .75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The SSO has approved this activity for up to .75 self-assessment credit which meets the requirement of the self-assessment component of the American Board of Surgery (ABS) Continuous Certification Program.

Requirements for Earning Credit and Method of Participation

This activity consists educational content, a self-assessment exam, and an evaluation. Learners must view the activity content, complete the self-assessment exam and achieve a minimum score of 75%. Learners will be able to review the content and repeat the self-assessment exam as many times as needed. Upon achieving a score of 75% or higher, learners will be asked to complete a post-activity evaluation. A certificate of credit or participation will be available upon successful submission of the post-activity evaluation.

Estimated Time to Complete Activity

The estimated time to complete this entire activity is  .75 hours.

Release Date

           October 27, 2020

Expiration Date

           October 27, 2021


In accordance with the ACCME’s Accreditation Criteria, the Society of Surgical Oncology must ensure that anyone in position to control the content of this educational activity has disclosed all financial relationships with a commercial interest. All educational planners, authors, reviewers, and other individuals in a position to control or influence the content of this activity were required to disclose all financial relationships with any commercial interest that have occurred within the past 12 months. This includes the disclosure of financial relationships of a spouse or partner. The ACCME considers financial relationships to create conflicts of interest when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest. The ACCME defines a commercial interest as “any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients.” ACCME does not consider providers of clinical service directly to patients to be commercial interests.

The ACCME also requires that the Society of Surgical Oncology resolve any reported conflict of interest and ensure the educational content of this activity is vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. If you perceive bias while participating in this activity, please advise us of the circumstances when completing your post-activity evaluation form.

All identified conflicts of interests have been resolved.

Planners, Moderators and Faculty

Christina Angeles, MD has disclosed no financial relationships.

Giorgos Karakousis, MD has disclosed no financial relationships.

Tina Hieken, MD has disclosed the following financial relationships: Genentech – Research Grant, Research Support.

David Ollila, MD has disclosed no financial relationships.

Jonathan Zager, MD has disclosed the following financial relationships: Pfizer - Speakers Bureau; Sun Pharma - Speakers Bureau; Castle Biosciences - Consultant, Research Funding; Philogen - Consultant, Research Funding; Novartis - Advisory Board; Merck - Advisory Board; Sanofi Dash Regeneron - Advisory Board; Delcath - Grant Funding, Advisory Board, Research Funding; Amgen - Consultant, Research Funding; Provectus - Research Funding


Hans Schoellhammer, MD has disclosed no financial relationships.

John Hamner, MD has disclosed no financial relationships.


Patti Stella, CAE, CHCP, Director of Education, Society of Surgical Oncology, has disclosed the following financial relationships: Horizon Pharmaceutical PLC – Stocks; Biotech – Stocks.


The primary purpose of the Society of Surgical Oncology's enduring material is educational. Information, as well as technologies, products, and/or services, discussed are intended to inform participants about the knowledge, techniques, and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty, and the Society of Surgical Oncology disclaims any and all liability for damages to any individual using the materials and for all claims which may result from the use of information, technologies, products, and/or services discussed.

Disclosure of Unlabeled Use

This educational activity may include discussions of unlabeled/unapproved uses of drugs or devices. Participants are advised to refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Opinions expressed in this educational activity are those of the expert contributors and do not necessarily represent the views of the Society of Surgical Oncology or any other organization associated with this activity.

Privacy and Confidentiality

For information about the Society of Surgical Oncology’s privacy policy and associated disclaimer, please visit this site:

System Requirements

System requirements for this activity can be found by clicking the Help button. For technical support, please contact us at

Availability: On-Demand
Available Oct 27, 2020 to Oct 27, 2021
Cost: Member: $0.00
Non-Member: $25.00
International Member : $0.00
International Non-Member: $25.00
Resident Member: $0.00
Resident Non-Member: $25.00
Fellow Member: $0.00
Fellow Non-Member: $25.00
Post Fellow Member: $25.00
Post Fellow Non-member: $25.00
Credit Offered: 0.75 CME Credit
0.75 CME / Self-Assessment Point
0.75 Participation Credit
Powered By